Nitto Denko Corporation established a new company, Nitto BioPharma Inc., with a focus on pharmaceutical development. Nitto has been conducting their first anti-liver fibrosis drug program (ND-L02-s0201), which is now in clinical trials in the US, Europe and Japan, and has several other pipelines of intractable diseases in the discovery stage. Along with the establishment of the new company, Nitto plans to set up a new facility mid-2016 in the center of the Life Sciences hub in San Diego, California.

Going forward, drug discovery and development ventures, such as an anti-fibrosis and other drugs will be conducted by Nitto and the new company. By establishing this new company with a focus on pharmaceutical development, Nitto will be able to further expand its future business options and opportunities for Nitto groups.